FDA Approves First Oral Carbapenem Utebzi with 58.5% Success Rate
SPRO•FDA approved Utebzi (tebipenem pivoxil), the first oral carbapenem, for adult complicated urinary tract infections including pyelonephritis based on PIVOT-PO trial showing non-inferiority (58.5% versus 60.2% IV comparator). Utebzi addresses over 3 million annual US cUTI cases with 34% treatment failure and $6 billion annual costs, potentially reducing hospital stays.
1. FDA Approves Utebzi for cUTIs
The FDA has approved Utebzi (tebipenem pivoxil) for adult patients with complicated urinary tract infections, including pyelonephritis, who have limited or no alternative oral treatment options. This marks the first oral carbapenem antibiotic approved in the US, offering a new outpatient therapy for severe resistant infections.
2. PIVOT-PO Trial Demonstrates Non-Inferiority
In the pivotal PIVOT-PO phase III trial, oral tebipenem pivoxil (600 mg every six hours) achieved a 58.5% composite clinical cure and microbiological eradication rate versus 60.2% for intravenous imipenem-cilastatin (500 mg) (adjusted difference −1.3%; 95% CI −7.5%, 4.8%). Adverse events were primarily mild to moderate diarrhea and headache, with no serious safety signals.
3. Significant Market Potential
More than 3 million US cUTI cases occur annually with up to 34% treatment failure, generating over $6 billion in healthcare costs. The availability of an effective oral carbapenem could shift care from hospitals to outpatient settings, reducing resource use and improving patient quality of life.
4. Partnership and Commercialization Timeline
Under an exclusive global licensing agreement, GSK holds commercialization rights outside select Asian territories while Spero Therapeutics conducted the PIVOT-PO study. Utebzi is anticipated to be available to US patients by the end of 2026 following manufacturing scale-up and distribution preparations.
